Skip to search formSkip to main contentSkip to account menu

UNBS 1450

Known as: UNBS-1450, UNBS1450 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cardenolides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
UNBS 1450 from as a regulator of signaling pathways involved in proliferation and cell death
HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they… 
2017
2017
Cardiac Glycosides as Novel Modulators of Cancer Cell Survival
Cardiac glycosides (CGs) were initially described as a cure for cardiovascular diseases. More recently a correlation between CG… 
Review
2014
Review
2014
Exploring novel formulations and new classes of anticancer drugs in solid tumors
Many current anticancer drugs have non-ideal pharmaceutical and pharmacological properties, which can lead to adverse… 
2014
2014
Salvianolic acid A, a novel matrix metalloproteinase-9 inhibitor, reduces microvascular damage induced by hypertension
2009
2009
Structurally unique Na+/K+-ATPase antagonist UNBS1450: the first hemi-synthetic cardenolide with marked anti-tumor activity to enter clinical trials.
2008
2008
UNBS1450, a novel cardenolide that inhibits sodium pump alpha1 subunits which are overexpressed in glioblastomas.
2006
2006
The cardenolide UNBS 1450 is able to deactivate nuclear factor K B – mediated cytoprotective effects in human non – small cell lung cancer cells
Non–small cell lung cancers (NSCLC) are associated with very dismal prognoses, and adjuvant chemotherapy, including irinotecan… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)